Population pharmacokinetics, efficacy, and safety of moxetumomab pasudotox in patients with relapsed or refractory hairy cell leukaemia

AIMS: To characterize the pharmacokinetics (PK) of moxetumomab pasudotox, an anti‐CD22 recombinant immunotoxin, in adults with relapsed or refractory hairy cell leukaemia, we examined data from a phase 1 study (Study 1001; n = 49) and from the pivotal clinical study (Study 1053; n = 74). METHODS: Da...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Clin Pharmacol
Main Authors: Kuruvilla, Denison, Chia, Yen Lin, Balic, Kemal, Yao, Nai Shun, Kreitman, Robert J., Pastan, Ira, Li, Xia, Standifer, Nathan, Liang, Meina, Tseng, Chih‐Ming, Faggioni, Raffaella, Roskos, Lorin
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7318999/
https://ncbi.nlm.nih.gov/pubmed/32077130
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.14250
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados